Akero Therapeutics Inc [AKRO] stock prices are up 2.88% to $39.61 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AKRO shares have gain 4.02% over the last week, with a monthly amount drifted -12.13%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akero Therapeutics Inc [NASDAQ: AKRO] stock has seen the most recent analyst activity on January 30, 2025, when BofA Securities upgraded its rating to a Buy and also boosted its price target to $63 from $35. Previously, H.C. Wainwright reaffirmed its Buy rating on January 27, 2025, and elevated its price target to $72. On November 18, 2024, Citigroup initiated with a Buy rating and assigned a price target of $65 on the stock. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $69 as its price target on September 19, 2023. UBS started tracking with a Buy rating for this stock on August 28, 2023, and assigned it a price target of $83. In a note dated January 27, 2023, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $40 to $65.
The stock price of Akero Therapeutics Inc [AKRO] has been fluctuating between $17.86 and $58.40 over the past year. Currently, Wall Street analysts expect the stock to reach $46 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $39.61 at the most recent close of the market. An investor can expect a potential return of 16.13% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.32 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 38.78 points at the first support level, and at 37.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 40.51, and for the 2nd resistance point, it is at 41.42.
Ratios To Look Out For
It’s worth pointing out that Akero Therapeutics Inc [NASDAQ:AKRO]’s Current Ratio is 19.38. As well, the Quick Ratio is 19.38, while the Cash Ratio is 8.56.
Transactions by insiders
Recent insider trading involved Yale Catriona, Chief Development Officer, that happened on Apr 15 ’25 when 9073.0 shares were sold. President and CEO, Cheng Andrew completed a deal on Apr 10 ’25 to sell 30000.0 shares. Meanwhile, Chief Scientific Officer Rolph Timothy sold 6250.0 shares on Apr 07 ’25.
